Replies to post #5793 on Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[EM]

With a fully diluted O/S this should be at least 6$ with:

i. KIT-302, a successfully phase 3 drug (general care) with a multi billion addressable market;

ii. NT219, a promising oncological drug ready for the IND, founded by the wolf price awarded Alexander Levitzki.


Lot of catalysts ahead.